{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:05:04Z","timestamp":1790629504101,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejso.2011.08.138","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T05:51:43Z","timestamp":1317016303000},"page":"971-977","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases"],"prefix":"10.1016","volume":"37","author":[{"given":"J.M.","family":"Classe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jaffre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dejode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dravet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berton Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Loussouarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2011.08.138_bib1","first-page":"7","article-title":"The frequency of cancer in France in year 2002, and trends since 1968","volume":"93","author":"Hill","year":"2006","journal-title":"Bull Cancer"},{"issue":"24","key":"10.1016\/j.ejso.2011.08.138_bib2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl. 8","key":"10.1016\/j.ejso.2011.08.138_bib3","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ejso.2011.08.138_bib4","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib5","first-page":"727","article-title":"Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma","volume":"30","author":"Skirnisdottir","year":"2007","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/gyno.1997.4909","article-title":"Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens","volume":"68","author":"Roland","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdj097","article-title":"A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients","volume":"17","author":"Viens","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","article-title":"\"Recurrence within 6 months of platinum therapy\": an adequate definition of \"platinum-refractory\" ovarian cancer?","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"9375","key":"10.1016\/j.ejso.2011.08.138_bib9","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejso.2011.08.138_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2004.07.033","article-title":"Tertiary cytoreduction in patients with recurrent ovarian carcinoma","volume":"95","author":"Leitao","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2011.08.138_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2011.08.138_bib12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2009.05.004","article-title":"Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome","volume":"114","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2008.01.039","article-title":"Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"109","author":"Ferrandina","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2011.08.138_bib16","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0090-8258(03)00342-1","article-title":"Future directions in the surgical management of ovarian cancer","volume":"90","author":"Berman","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2004.09.018","article-title":"Critical evaluation of secondary cytoreduction in recurrent ovarian cancer","volume":"95","author":"Munkarah","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2011.08.138_bib18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2011.08.138_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0029-7844(02)01977-4","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"99","author":"Tay","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ejso.2011.08.138_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/gyno.2001.6143","article-title":"Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer","volume":"81","author":"Munkarah","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1006\/gyno.2000.5992","article-title":"Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer","volume":"79","author":"Gadducci","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3802\/jgo.2009.20.2.101","article-title":"Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer","volume":"20","author":"Bae","year":"2009","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2011.08.138_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/gyno.1995.1099","article-title":"Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response","volume":"57","author":"Vaccarello","year":"1995","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2011.08.138_bib25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection","volume":"92","author":"Onda","year":"2005","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib26","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"Berek","year":"1983","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejso.2011.08.138_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2011.08.138_bib28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl. 10","key":"10.1016\/j.ejso.2011.08.138_bib29","doi-asserted-by":"crossref","first-page":"x235","DOI":"10.1093\/annonc\/mdl266","article-title":"The role of surgery in advanced and recurrent ovarian cancer","volume":"17","author":"du Bois","year":"2006","journal-title":"Ann Oncol"},{"issue":"642","key":"10.1016\/j.ejso.2011.08.138_bib30","first-page":"e1","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199(6)","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2011.08.138_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejso.2011.08.138_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2009.08.025","article-title":"Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes","volume":"115","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2011.08.138_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/gyno.2002.6748","article-title":"Treatment preferences in recurrent ovarian cancer","volume":"86","author":"Donovan","year":"2002","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798311005348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798311005348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T21:51:08Z","timestamp":1543528268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798311005348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0748798311005348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2011.08.138","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}